No abstract

New York City Transit’s automated fare collection system, known as MetroCard, is an entry-only system that records the serial number of the MetroCard and the time and location (subway turnstile or bus number) of each use. A methodology that estimates station-to-station origin and destination (O-D) trip tables by using this MetroCard information is described. The key is to determine the sequence of trips made throughout a day on each MetroCard. This is accomplished by sorting the MetroCard information by serial number and time and then extracting, for each MetroCard, the sequence of the trips and the station used at the origin of each trip. A set of straightforward algorithms is applied to each set of MetroCard trips to infer a destination station for each origin station. The algorithms are based on two primary assumptions. First, a high percentage of riders return to the destination station of their previous trip to begin their next trip. Second, a high percentage of riders end their last trip of the day at the station where they began their first trip of the day. These assumptions were tested by using travel diary information collected by the New York Metropolitan Transportation Council. This diary information confirmed that both assumptions are correct for a high percentage (90%) of subway users. The output was further validated by comparing inferred destination totals to station exit counts by time of day and by estimating peak load point passenger volumes by using a trip assignment model. The major applications of this project are to describe travel patterns for service planning and to create O-D trip tables as input to a trip assignment model. The trip assignment model is used to determine passenger volumes on trains at peak load points and other locations by using a subway network coded with existing or modified service. These passenger volumes are used for service planning and scheduling and to quantify travel patterns. This methodology eliminates the need for periodic systemwide O-D surveys that are costly and time-consuming. The new method requires no surveying and eliminates sources of response bias, such as low response rates for certain demographic groups. The MetroCard market share is currently 80% and increasing. MetroCard data are available continuously 365 days a year, which allows O-D data estimation to be repeated for multiple days to improve accuracy or to account for seasonality.

No abstract

Direct intramyocardial injection may permit local delivery of protein and gene therapy agents for myocardial and coronary artery disease. Little is known about the immediate fate of materials administered via percutaneous endomyocardial catheters or via surgical epicardial injection. In this study, we use a novel method to evaluate the acute retention of agents injected directly into the myocardium, compare epicardial with the percutaneous endocardial and postmortem delivery, and evaluate the influence of injectate volume on myocardial retention. Fifteen 40-50 kg pigs underwent overlapping myocardial injections using a percutaneous endomyocardial catheter, an epicardial needle via an open chest, and epicardial needle postmortem. Multiple distinct 15 micro neutron-activated microsphere species were used as tracers. Two or three myocardial walls were injected in each animal using 3.5 mm, 27-28 gauge needles at varying injectate volumes. Animals were sacrificed immediately. Myocardial walls were divided and multiple microsphere species were quantified. In an additional study, nine 70 kg pigs underwent percutaneous endomyocardial injections with replication-deficient adenovirus encoding for the production of lac-Z. The injectate volume was varied, while the viral particle number remained constant. The animals were sacrificed 5 days after the percutaneous injections; the heart, liver, and spleen were collected for beta-galactosidase activity. Endomyocardial injection was associated with 43% +/- 15% microsphere retention, compared with 15% +/- 21% (P < 0.01) retention of open chest epicardial injection and 89% +/- 60% (P < 0.01) for postmortem injection. Reducing the injectate volume from 100 to 10 microL improved microsphere retention (P = 0.01). There was a trend toward improved viral transfection associated with smaller injection volumes. Despite direct intramyocardial administration, a significant fraction of injectate is not retained locally. Catheter-based needle endomyocardial injection is associated with equivalent or superior injectate retention compared with open chest epicardial injection. Proportionately, more injectate may be retained at lower volumes. Loss may involve a combination of channel leakage, venous, and lymphatic return.

Paclitaxel (PTX), a microtubule-active drug, causes mitotic arrest leading to apoptosis in certain tumor cell lines. Here we investigated the effects of PTX on human arterial smooth muscle cell (SMC) cells. In SMC, PTX caused both (a) primary arrest in G 1 and (b) post-mitotic arrest in G 1 . Post-mitotic cells were multinucleated (MN) with either 2C (near-diploid) or 4C (tetraploid) DNA content. At PTX concentrations above12 ng/ml, MN cells had 4C DNA content consistent with the lack of cytokinesis during abortive mitosis. Treatment with 6-12 ng/ml PTX yielded MN cells with 2C DNA content. Finally, 1-6 ng/ml of PTX, the lowest concentrations that affected cell proliferation, caused G 1 arrest without multinucleation. It is important that PTX did not cause apoptosis in SMC. The absence of apoptosis could be explained by mitotic exit and G 1 arrest as well as by low constitutive levels of caspase expression and by p53 and p21 induction. Thus, following transient mitotic arrest, SMC exit mitosis to form MN cells. These post-mitotic cells were subsequently arrested in G 1 but maintained normal elongated morphology and were viable for at least 21 days. We conclude that in SMC PTX causes post-mitotic cell cycle arrest rather than cell death.

Recombinant adenoviruses are the most efficient vectors with which to perform arterial gene transfer. Previous in vivo studies of adenovirus-mediated arterial transfection, however, have been performed using normal or endothelium-denuded arteries. It is unclear whether these results can be extended to atherosclerotic arteries. Accordingly, this study was designed to (a) assess the feasibility of adenovirusmediated gene transfer to atherosclerotic lesions, and (b) compare the transfection efficiency, anatomic distribution of transfected cells, and duration of transgene expression achieved in normal versus atherosclerotic arteries. A recombinant adenovirus including a nuclear-targeted (-galactosidase gene was percutaneously delivered to the iliac artery of normal (n = 25) and atherosclerotic (n = 25) rabbits. Transgene expression, assessed by morphometric as well as chemiluminescent analyses, was documented in all normal and atherosclerotic arteries between 3 and 14 d after gene transfer, but was undetectable at later time points. Transfected cells were identified as smooth muscle cells located in the media of normal arteries, and in the neointima and the vasa-vasora of atherosclerotic arteries. Two percent of medial cells, but only 0.2% of medial and neointimal cells expressed the transgene in normal and atherosclerotic arteries, respectively (P = 0.0001). Similarly, nuclear ,B-galactosidase activity was higher in normal than in atherosclerotic arteries (3.2 vs. 0.8 mU/mg protein, P = 0.02). These findings indicate that atherosclerosis reduces the transfection efficiency which can be achieved with adenoviral vectors, and thus constitutes a potential limitation to adenovirus-based, arterial gene therapy. (J. Clin. Invest. 1995. 95:2662-2671

Many large transit systems use automatic fare collection (AFC) systems. Most AFC systems were designed solely for revenue management, but they contain a wealth of customer use data that can be mined to create inputs to operations planning and demand forecasting models for transportation planning. More detailed information than could ever be collected by any travel survey is potentially available if it is assumed that the transactional data can be processed to produce the desired information. Previous work in this field focused primarily on rail transit, since boardings at fixed stations are easier to locate than boardings of buses, which move around. This paper presents a case study for the Metropolitan Transit Authority's New York City Transit, a transit system in which a rider swipes a fare card only to enter a station or board a bus. This is the first work to include trips by all transit modes in a system that records the transaction only on rider entry, which is significantly more challenging because all the alighting locations need to be inferred and the bus boarding locations need to be estimated. No location information (from automated vehicle location technology or a Global Positioning System) was available for buses. Software that processes the 7 million–plus daily transactions and that creates a data set of linked transit trips was created. The data set can then be analyzed by using geographic information system-based query software to create reports, maps, origin–destination matrices, load profiles, and new data sets. Subway journeys are assigned by using a schedule-based shortest-path algorithm.

(1) Efficient, adenovirus-mediated, arterial gene transfer to endothelial and/or smooth muscle cells is feasible by percutaneous, clinically applicable techniques. (2) Consistent transfection of medial smooth muscle cells may be achieved when the endothelial layer is abraded. (3) Medial transfection is more efficient when an HBC, rather than a DBC, is used. (4) Percutaneous delivery of the adenoviral vector via HBC results in site-specific arterial gene transfer. Very-low-level extra-arterial transfection may occur, however, when the DBC is used.